Insight Brief
Alan Wookey | August 22, 2016

The Power of the Central Laboratory for Immuno-Oncology Drug Development

Sponsors who partner with a global central laboratory should expect optimized outcomes resulting from a depth of immuno-oncology and technological expertise and harmonized processes. The Central Laboratory has been pivotal in testing and providing data that are needed to determine inclusion and exclusion criteria and to monitor safety profiles.

Central labs contribute to the identification of responders versus non-responders (whether it be for efficacy, safety, or dosage) and use biomarkers for proof of mechanism of action or resistance and patient selection. Approvals for assays provided by central laboratories through their diagnostic offerings are also well documented.

Download this insight brief now to discover the power behind these central laboratories in immuno-oncology drug development.

Alan Wookey, Global Science Lead, Companion Diagnostics & Scientific Advisor, Oncology

Related Services:
Planning and implementing biomarker testing for immuno-oncology trials

Exploring the challenges with the diverse clinical biomarker requirements

From eligibility to CDx: developing and implementing effective biomarker strategies for Immuno-oncology trials

Gene expression for keeping pace with immuno-oncology breakthroughs and biomarker identification

When and how to use gene expression profiling

Central Laboratory Considerations for Deploying a Global Companion Diagnostics Solution

World CDx Europe 2018

Read More